Highlights

  • Micro-X (ASX:MX1) is advancing its medical imaging technology portfolio across mobile X-ray, stroke diagnosis and security applications.
  • The company secured additional funding support through an $8 million convertible note Facility to support growth initiatives.
  • FY26 half-year results showed Revenue growth supported by a major Rover order and project activity.
  • Micro-X is focusing on cost discipline, commercial expansion and development of next-generation imaging solutions.

Micro-X (ASX:MX1) is continuing to develop its position in the medical technology sector through its lightweight X-ray imaging platforms and emerging healthcare applications. The Adelaide-based company is focused on commercialising its carbon nanotube-enabled technology across mobile medical imaging, stroke diagnostics and security screening markets.

During 2026, Micro-X entered a new phase of development with changes to its Leadership structure, a strategic review of operations and additional funding to support its growth priorities. The company is aiming to improve commercial execution while advancing products including Rover, its mobile digital radiography platform, and Head CT, its portable brain imaging technology designed for rapid stroke diagnosis.

Strategic Shift

Micro-X announced a leadership transition in August 2026, appointing Dr Brian Gonzales as Group Chief Executive Officer. The appointment formed part of a broader strategic reset aimed at improving operational focus, strengthening financial discipline and prioritising key commercial opportunities.

The company identified three main areas of focus for FY27, including accelerating medical CT development, improving project cost management and refining the sales approach for Rover following an external review.

Alongside the leadership change, Micro-X secured an $8 million funding package through secured convertible notes. The Capital raising is intended to support continued development of its medical imaging products, commercial initiatives and Working Capital requirements.

The funding arrangement provides additional financial flexibility as the company works towards expanding commercial adoption of its technology platforms.

Financial Performance

Micro-X’s half-year results for the six months ended 31 December 2025 showed increased revenue activity, supported by product sales and project contributions.

The company reported Operating Revenue of $10.1 million for the period, compared with $4.0 million in the prior corresponding period. Product revenue contributed $4.4 million, while project revenue contributed $5.7 million.

The improvement was supported by a significant Rover order from Malaysia’s Ministry of Health, which contributed to higher revenue during the reporting period.

Despite revenue growth, Micro-X remained loss-making as it continued investing in product development and commercial expansion. The company recorded a net loss of $6.6 million for the half year, while operating EBITDA was negative $6.4 million.

The company’s focus remains on improving commercial traction, controlling costs and extending its financial capacity while progressing its technology pipeline.

Growth Areas

Rover remains one of Micro-X’s key commercial platforms. The mobile digital radiography system is designed to provide portable imaging capability in healthcare environments where traditional equipment may not be practical.

The company continues to pursue additional opportunities for Rover across healthcare markets, with a focus on expanding customer adoption and strengthening its sales pipeline.

Another major development opportunity is Head CT, a lightweight CT scanner designed to support faster stroke diagnosis closer to the point of patient care. The technology is being developed to address challenges associated with traditional CT systems, particularly in emergency and mobile healthcare settings.

Micro-X is also maintaining activity in security and defence markets, where its technology platform has applications in screening and detection systems. These programs provide additional commercial opportunities beyond healthcare imaging.

Funding Details

The $8 million convertible note facility represents a key component of Micro-X’s recent capital strategy.

The notes have a three-year Maturity period and are intended to provide funding support for the company’s ongoing product development and commercial activities. The facility includes participation from existing investors, management-related parties and institutional participants.

Micro-X has indicated that proceeds from the funding will support Head CT development, Rover commercial activities and general working capital requirements.

The company has also outlined cost reduction initiatives, targeting annualised savings as part of its broader focus on improving operational efficiency.

Key Focus Areas

Investors will continue to monitor Micro-X’s ability to convert its technology pipeline into sustainable commercial revenue.

Progress in Rover sales expansion will be an important factor, particularly as the company works to strengthen its commercial approach and build recurring customer relationships.

Head CT development will also remain a key milestone, with future progress dependent on clinical advancement, regulatory pathways and market adoption.

The company’s ability to manage costs, maintain funding flexibility and secure additional commercial contracts will be important factors in assessing the effectiveness of its strategic reset.

Risks

Micro-X remains exposed to several risks associated with developing and commercialising advanced medical technologies.

The company continues to operate with ongoing losses, meaning future growth depends on successful product commercialisation, contract wins and effective capital management.

Revenue concentration across major contracts and government-linked programs may create variability in financial performance due to timing differences and procurement cycles.

The convertible note facility may also result in Shareholder dilution if conversion occurs, increasing the company’s Issued Capital over time.

Additionally, technologies such as Head CT require continued development, validation and regulatory progress before reaching broader commercial adoption.

Outlook

Micro-X enters the next phase of its development with a clearer focus on medical imaging opportunities, operational efficiency and commercial execution.

The company’s strategy centres on expanding Rover adoption, progressing Head CT development and leveraging its technology platform across healthcare and security applications.

While the company continues to face challenges associated with early-stage commercialisation and ongoing Investment requirements, the strategic reset and additional funding provide support for advancing key initiatives.

Future performance will depend on Micro-X’s ability to translate technological innovation into repeatable commercial growth while maintaining disciplined cost management.